Catalyst Wire Dossier Catalyst Wire Dossier

Suvorexant (MK-4305)

suvorexant · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Suvorexant (MK-4305), covering 2024-05-20 to 2024-05-20. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085) [Phase 3]

See pricing